Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2012-09-30
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis
NCT01799642
Extrapulmonary Effects of Cystic Fibrosis on Physical Activity of Adult Patients.
NCT01848392
Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis
NCT03873688
Respiratory Muscle Training in CF Patients
NCT03190031
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Several studies have showed a connection between weaknesses of respiratory muscles in CF and deficits of CFTR in the muscle; sustain infection of pseudomonas; lower than normal tension time index and low fat free mass \[3-6\]. Weakness of the respiratory muscle may insinuate insufficient cough in CF patients.
Effective cough is initiated in several mechanical stages: a) inhaling a variable amount of air, b) closure of the glottis, c) contraction of respiratory muscles, and d) forced expiration to residual volume \[7-13\] A voluntary cough flow volume (C-FVC) profile therefore, incorporates the characteristics of the forced expiratory flow volume curve (FEVC) in that the first "spike" represents the peak cough flow, and the volume exhaled by the cough corresponds with the vital capacity. The descending portion of the C-FVC including secondary spikes decrease in a linear fashion as lung volume goes down from total lung capacity to residual volume.10 similar to the FEVC flow decay. Any disturbance in either of the cough stages may impair its efficiency.
The aim of this study is to explore the information that can be gained on cough ability in a group of CF patients, by the performance of voluntary cough-flow-volume maneuver and in relation to the characteristics of a maximum expiratory flow-volume curve.
Study plan How does this advance the field? In this study we wish to evaluate for the first time the cough ability derived from the voluntary cough flow volume curve for detection of insufficient cough in patients with CF. We hope to show that the cough flow volume curve corresponds with changes in cough ability in these patients in relation to lung function deterioration.
What are the clinical implications? An objective following-up of cough ability deterioration may allow the opportunity to introduce special respiratory therapy for strengthening cough and ease secretion flow in these patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
8 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daphna Vilozni, PhD
Head of Pediatric Pulmonary Laboratory
References
Explore related publications, articles, or registry entries linked to this study.
Divangahi M, Matecki S, Dudley RW, Tuck SA, Bao W, Radzioch D, Comtois AS, Petrof BJ. Preferential diaphragmatic weakness during sustained Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med. 2004 Mar 15;169(6):679-86. doi: 10.1164/rccm.200307-949OC. Epub 2003 Dec 11.
Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. The influence of body composition on respiratory muscle, lung function and diaphragm thickness in adults with cystic fibrosis. J Cyst Fibros. 2007 Nov 30;6(6):384-90. doi: 10.1016/j.jcf.2007.02.006. Epub 2007 Apr 2.
Divangahi M, Balghi H, Danialou G, Comtois AS, Demoule A, Ernest S, Haston C, Robert R, Hanrahan JW, Radzioch D, Petrof BJ. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 2009 Jul;5(7):e1000586. doi: 10.1371/journal.pgen.1000586. Epub 2009 Jul 31.
Hayot M, Guillaumont S, Ramonatxo M, Voisin M, Prefaut C. Determinants of the tension-time index of inspiratory muscles in children with cystic fibrosis. Pediatr Pulmonol. 1997 May;23(5):336-43. doi: 10.1002/(sici)1099-0496(199705)23:53.0.co;2-i.
McCool FD, Leith DE. Pathophysiology of cough. Clin Chest Med. 1987 Jun;8(2):189-95.
Beardsmore CS, Wimpress SP, Thomson AH, Patel HR, Goodenough P, Simpson H. Maximum voluntary cough: an indication of airway function. Bull Eur Physiopathol Respir. 1987 Sep-Oct;23(5):465-72.
Pedersen OF, Lyager S, Ingram RH Jr. Airway dynamics in transition between peak and maximal expiratory flow. J Appl Physiol (1985). 1985 Dec;59(6):1733-46. doi: 10.1152/jappl.1985.59.6.1733.
Langlands J. The dynamics of cough in health and in chronic bronchitis. Thorax. 1967 Jan;22(1):88-96. doi: 10.1136/thx.22.1.88. No abstract available.
Bianchi C, Baiardi P. Cough peak flows: standard values for children and adolescents. Am J Phys Med Rehabil. 2008 Jun;87(6):461-7. doi: 10.1097/PHM.0b013e318174e4c7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-11-8709-OE-SMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.